Side-by-side comparison of AI visibility scores, market position, and capabilities
$19.3M revenue 2024 (+28% YoY); $61.8M funding; $43M Series C (Morgan Stanley); Blackstone/Nuveen/LaSalle customers; $10T transactions; 7 of top 10 RE investors; deal management leader
Dealpath is a real estate investment management platform founded in 2014 and headquartered in San Francisco. The company was created to solve a specific operational pain point for institutional real estate investors: deal pipeline, due diligence, and portfolio data were fragmented across spreadsheets, emails, and disconnected systems, making it difficult for investment teams to move quickly, maintain data integrity, or generate reliable reporting. Dealpath's mission is to be the system of record for institutional real estate investment management.\n\nThe platform provides structured deal pipeline management, due diligence workflow automation, document management, and portfolio analytics for acquisition, development, and asset management teams. Investment committees can track every deal from initial screening through closing with configurable workflows, approval gates, and audit trails. Dealpath integrates with Argus, Yardi, MRI, and major data providers to consolidate the real estate investment data ecosystem. Customers include some of the world's largest real estate investors — Blackstone, Nuveen, and LaSalle Investment Management — who use the platform to manage large acquisition pipelines and institutional-grade due diligence processes.\n\nDealpath generated $19.3 million in revenue in 2024, a 28% increase year-over-year, and has raised $61.8 million in total funding, including a $43 million Series C with participation from Morgan Stanley. The platform has facilitated oversight of more than $10 trillion in real estate transactions. Its focus on institutional-grade workflow rigor and deep integrations with the real estate data stack differentiate it from generic project management tools adapted for property investment.
Pasadena life science campus REIT (NYSE: ARE) with 39.7M RSF at $25.7B market cap; largest company lease ever (466,598 RSF/16-year pharma at San Diego Campus Point) and $3.12B 2024 revenue competing with Healthpeak for biotech lab REIT.
Alexandria Real Estate Equities, Inc. is a Pasadena, California-based life science real estate investment trust — publicly traded on the New York Stock Exchange (NYSE: ARE) as an S&P 500 REIT — operating as the preeminent owner, operator, and developer of collaborative life science, technology, and agtech Megacampus ecosystems in AAA innovation cluster locations including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland/DC, Research Triangle, and New York City. As of June 30, 2025, Alexandria has a $25.7 billion total market capitalization and manages 39.7 million rentable square feet (RSF) of operating properties and 4.4 million RSF of Class A/A+ properties under construction. In 2024, Alexandria reported $3.12 billion in revenue (+8.20%). The company executed its largest single lease in history — a 16-year agreement with a multinational pharmaceutical tenant for 466,598 RSF at the Campus Point Megacampus in San Diego (98.8% occupied). Executive Chairman and Founder: Joel Marcus; Co-CEOs: Stephen Richardson and Peter Moglia. Founded 1994.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.